The markets have roared higher over the past year, but few stocks have had the kind of run-up that developmental 3-D bioprinting company Organovo Holdings (NYSEMKT:ONVO) has. Organovo's stock has jumped by more than 125% over the past year, but this company has yet to generate any meaningful revenue, and its bioprinting technology has only caught on with a few partnerships, most recently one with the NIH to print tissue for research purposes.
However, is trouble on the horizon? This week, noted short-selling site Citron Research sent out a warning to investors over Organovo's stock. Among other issues, Citron noted the stock's lack of sell-side coverage and significant institutional ownership in questioning how the stock's jumped so far so fast.
Is Citron on to something with Organovo? In the video below, Motley Fool contributor Dan Carroll tells you what you need to know about the latest news swirling around this hot stock -- and whether or not you can believe in Organovo's stock's rapid rise.
The two biotech stocks that could transform your portfolio's potential
Biotech can be a growth investor's dream. The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.